This site contains information for UK healthcare professionals only on Xolair and chronic spontaneous urticaria.

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.¹

 

*Post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.²

DLQI, Dermatology Life Quality Index; IgE, immunoglobulin E.

References

1. Xolair^® (omalizumab) 150 mg Summary of Product Characteristics.
2. Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.